Does the media favor IMVT or SNDX?

In the previous week, Immunovant had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 8 mentions for Immunovant and 6 mentions for Syndax Pharmaceuticals. Immunovant's average media sentiment score of 0.35 beat Syndax Pharmaceuticals' score of 0.12 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SNDX or PCVX?

In the previous week, Vaxcyte had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 7 mentions for Vaxcyte and 6 mentions for Syndax Pharmaceuticals. Vaxcyte's average media sentiment score of 0.31 beat Syndax Pharmaceuticals' score of 0.12 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SNDX or KYMR?

In the previous week, Syndax Pharmaceuticals and Syndax Pharmaceuticals both had 6 articles in the media. Kymera Therapeutics' average media sentiment score of 0.64 beat Syndax Pharmaceuticals' score of 0.12 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SNDX or SYRE?

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.95 beat Syndax Pharmaceuticals' score of 0.12 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SNDX or PTGX?

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 6 mentions for Syndax Pharmaceuticals. Protagonist Therapeutics' average media sentiment score of 0.72 beat Syndax Pharmaceuticals' score of 0.12 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Syndax Pharmaceuticals (SNDX) Competitors

$18.34 -0.05 (-0.27%)

As of 04:00 PM Eastern

Compare

SNDX vs. IMVT, PCVX, KYMR, SYRE, and PTGX

Should you buy Syndax Pharmaceuticals stock or one of its competitors? MarketBeat compares Syndax Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Syndax Pharmaceuticals include Immunovant (IMVT), Vaxcyte (PCVX), Kymera Therapeutics (KYMR), Spyre Therapeutics (SYRE), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Syndax Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Syndax Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Syndax Pharmaceuticals	$172.35M	9.43	-$285.42M	-$2.79	N/A

Immunovant has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Immunovant's return on equity of -65.66% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

In the previous week, Immunovant had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 8 mentions for Immunovant and 6 mentions for Syndax Pharmaceuticals. Immunovant's average media sentiment score of 0.35 beat Syndax Pharmaceuticals' score of 0.12 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant currently has a consensus target price of $37.33, suggesting a potential upside of 19.85%. Syndax Pharmaceuticals has a consensus target price of $42.55, suggesting a potential upside of 131.98%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

47.1% of Immunovant shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Syndax Pharmaceuticals beats Immunovant on 9 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Vaxcyte?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

96.8% of Vaxcyte shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 3.3% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Syndax Pharmaceuticals currently has a consensus target price of $42.55, indicating a potential upside of 131.98%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 83.25%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Vaxcyte has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Vaxcyte's return on equity of -32.51% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Vaxcyte	N/A	-32.51%	-29.51%

Syndax Pharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

In the previous week, Vaxcyte had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 7 mentions for Vaxcyte and 6 mentions for Syndax Pharmaceuticals. Vaxcyte's average media sentiment score of 0.31 beat Syndax Pharmaceuticals' score of 0.12 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Syndax Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.43	-$285.42M	-$2.79	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Summary

Syndax Pharmaceuticals beats Vaxcyte on 9 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Kymera Therapeutics?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Syndax Pharmaceuticals and Syndax Pharmaceuticals both had 6 articles in the media. Kymera Therapeutics' average media sentiment score of 0.64 beat Syndax Pharmaceuticals' score of 0.12 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has a net margin of -111.88% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Syndax Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Syndax Pharmaceuticals currently has a consensus price target of $42.55, suggesting a potential upside of 131.98%. Kymera Therapeutics has a consensus price target of $118.10, suggesting a potential upside of 61.38%. Given Syndax Pharmaceuticals' higher possible upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

Syndax Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.43	-$285.42M	-$2.79	N/A
Kymera Therapeutics	$39.21M	153.52	-$311.35M	-$3.57	N/A

Summary

Kymera Therapeutics beats Syndax Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Spyre Therapeutics?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

80.4% of Spyre Therapeutics shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Spyre Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.43	-$285.42M	-$2.79	N/A
Spyre Therapeutics	$890K	7,173.57	-$155.20M	-$2.08	N/A

Syndax Pharmaceuticals currently has a consensus price target of $42.55, suggesting a potential upside of 131.98%. Spyre Therapeutics has a consensus price target of $90.25, suggesting a potential upside of 22.76%. Given Syndax Pharmaceuticals' higher possible upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.95 beat Syndax Pharmaceuticals' score of 0.12 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, indicating that its share price is 205% more volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Spyre Therapeutics' return on equity of -42.88% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Spyre Therapeutics beats Syndax Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Protagonist Therapeutics?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Syndax Pharmaceuticals currently has a consensus price target of $42.55, indicating a potential upside of 131.98%. Protagonist Therapeutics has a consensus price target of $115.21, indicating a potential upside of 20.76%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Syndax Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Syndax Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

98.6% of Protagonist Therapeutics shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 6 mentions for Syndax Pharmaceuticals. Protagonist Therapeutics' average media sentiment score of 0.72 beat Syndax Pharmaceuticals' score of 0.12 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.43	-$285.42M	-$2.79	N/A
Protagonist Therapeutics	$46.02M	133.33	-$130.15M	-$1.81	N/A

Syndax Pharmaceuticals has a net margin of -111.88% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Summary

Protagonist Therapeutics beats Syndax Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNDX vs. The Competition

Export

Metric	Syndax Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.63B	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-6.57	17.78	22.39	24.18
Price / Sales	9.43	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	24.78	6.63	9.84	6.72
Net Income	-$285.42M	$24.20M	$3.57B	$337.19M
7 Day Performance	-6.48%	-3.24%	-1.16%	0.48%
1 Month Performance	-3.88%	0.53%	3.85%	5.07%
1 Year Performance	63.90%	47.24%	27.40%	34.25%

Syndax Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNDX Syndax Pharmaceuticals	2.5605 of 5 stars	$18.34 -0.3%	$42.55 +132.0%	+67.5%	$1.63B	$172.35M	N/A	110	Analyst Forecast Insider Trade
IMVT Immunovant	2.3497 of 5 stars	$34.33 +0.6%	$35.33 +2.9%	+100.6%	$6.97B	N/A	N/A	120	Gap Up
PCVX Vaxcyte	2.7424 of 5 stars	$47.78 +0.8%	$86.00 +80.0%	+35.4%	$6.89B	N/A	N/A	160	Insider Trade
KYMR Kymera Therapeutics	2.103 of 5 stars	$78.70 -2.4%	$118.10 +50.1%	+65.3%	$6.48B	$39.21M	N/A	170
SYRE Spyre Therapeutics	2.5499 of 5 stars	$73.96 -0.5%	$90.25 +22.0%	+349.1%	$6.42B	$890K	N/A	73

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNDX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. IMVT, PCVX, KYMR, SYRE, and PTGX

How does Syndax Pharmaceuticals compare to Immunovant?

Summary

How does Syndax Pharmaceuticals compare to Vaxcyte?

Summary

How does Syndax Pharmaceuticals compare to Kymera Therapeutics?

Summary

How does Syndax Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Syndax Pharmaceuticals compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. IMVT, PCVX, KYMR, SYRE, and PTGX

How does Syndax Pharmaceuticals compare to Immunovant?

Which has better earnings and valuation, IMVT or SNDX?

Is IMVT or SNDX more profitable?

Which has more volatility and risk, IMVT or SNDX?

Does the media favor IMVT or SNDX?

Do analysts recommend IMVT or SNDX?

Do insiders and institutionals have more ownership in IMVT or SNDX?

Summary

How does Syndax Pharmaceuticals compare to Vaxcyte?

Do institutionals & insiders have more ownership in SNDX or PCVX?

Do analysts prefer SNDX or PCVX?

Is SNDX or PCVX more profitable?

Which has more volatility and risk, SNDX or PCVX?

Does the media prefer SNDX or PCVX?

Which has preferable valuation & earnings, SNDX or PCVX?

Summary

How does Syndax Pharmaceuticals compare to Kymera Therapeutics?

Does the media refer more to SNDX or KYMR?

Is SNDX or KYMR more profitable?

Which has more volatility and risk, SNDX or KYMR?

Do analysts recommend SNDX or KYMR?

Which has stronger valuation and earnings, SNDX or KYMR?

Summary

How does Syndax Pharmaceuticals compare to Spyre Therapeutics?

Do insiders & institutionals believe in SNDX or SYRE?

Which has better earnings & valuation, SNDX or SYRE?

Do analysts rate SNDX or SYRE?

Does the media refer more to SNDX or SYRE?

Which has more volatility and risk, SNDX or SYRE?

Is SNDX or SYRE more profitable?

Summary

How does Syndax Pharmaceuticals compare to Protagonist Therapeutics?

Do analysts recommend SNDX or PTGX?

Which has more volatility and risk, SNDX or PTGX?

Do institutionals and insiders have more ownership in SNDX or PTGX?

Does the media refer more to SNDX or PTGX?

Which has better earnings & valuation, SNDX or PTGX?

Is SNDX or PTGX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools